Martinsried/Munich, September 22, 2008. The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) will present at the UBS Global Life Science Conference in New York. The presentation will be made by Dr. Thomas Klaue, Chief Financial Officer of MediGene AG, at 12:30 p.m. local time (18:30 CET) on September 24, 2008. Dr. Klaue will give a business summary, and provide an update on the latest business developments. The presentation will be webcast live on the internet, and a replay will also be available from September 24 at www.medigene.com.
MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. MediGene has several drug candidates in clinical development, including EndoTAG(TM)-1 and RhuDex(TM), which could both offer substantial sales returns. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases.
This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. EndoTAG(TM) and MediGene® are trademarks of MediGene AG, RhuDex(TM) is a trademark of MediGene Ltd. These trademarks may be owned or licensed in select locations only.
MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA.
Contact MediGene AG
E-mail: investor@medigene.com
Fax:++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Georg Dönges, Public Relations, Tel.: ++49 - 89 - 85 65 - 3317
Dr. Michael Nettersheim / Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946
